Amgen receives FDA approval for Kyprolis combination therapy to treat multiple myeloma
The US Food and Drug Administration (FDA) has granted approval for Amgens’ Kyprolis (carfilzomib) combination therapy to treat patients with relapsed or refractory multiple myeloma.